The present paper reports a polypeptide comprising a First and a Second polypeptide polypeptide comprising direction from n-terminal to c-terminal region at least a portion of an immunoglobulin Hinge, which comprises one or more cysteine residues, the CH2 domain The CH3 Domain Immunoglobulin and immunoglobulin(i) in which the first and the second polypeptide h310a h433a include mutations, and y436a, or (ii) the first and the second polypeptide l251d l314d include mutations, and l432d, or (iii) the first and the second polypeptide l251s l314s include mutations, and l432s.Claim 1: a polypeptide comprising a First and a Second polypeptide polypeptide, comprising in each direction from n-terminal to c-terminal region at least a portion of an immunoglobulin Hinge, which comprises one or more cysteine residues, a inmunog CH2 domain Lobulina CH3 domain and an immunoglobulin(i) in which the first and the second polypeptide h310a h433a include mutations, and y436a, or (ii) the first and the second polypeptide l251d l314d include mutations, and l432d, or (iii) the first and the second polypeptide l251s l314s include mutations, and l432s.Claim 15: a Pharmaceutical formulation comprising a polypeptide according to any one of claims 1 to 12, and optionally a pharmaceutically acceptable vehicle.Claim 17: a polypeptide according to any one of claims 1 to 12 for use in Transport of a soluble receptor ligand from the eye through the barrier of Blood - ocular Blood Circulation.En el presente documento se comunica un polipéptido que comprende un primer polipéptido y un segundo polipéptido que comprende en dirección de N-terminal a C-terminal al menos una porción de una región bisagra de inmunoglobulina, que comprende uno o más restos de cisteína, un dominio CH2 de inmunoglobulina y un dominio CH3 de inmunoglobulina, en el que i) el primer y el segundo polipéptido comprenden las mutaciones H310A, H433A y Y436A, o ii) el primer y el segundo polipéptido comprenden las mutaciones L251D, L
